Midwest Trust Co Invests $321,000 in Cencora, Inc. $COR

Midwest Trust Co bought a new position in shares of Cencora, Inc. (NYSE:COR) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,072 shares of the company’s stock, valued at approximately $321,000.

A number of other institutional investors have also bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC lifted its stake in shares of Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the period. Costello Asset Management INC bought a new stake in Cencora in the first quarter worth approximately $28,000. University of Texas Texas AM Investment Management Co. bought a new stake in Cencora in the first quarter worth approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new position in Cencora in the second quarter valued at approximately $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Cencora during the 2nd quarter worth approximately $61,000. Institutional investors own 97.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Evercore ISI set a $400.00 price target on shares of Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Wells Fargo & Company lifted their price target on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Finally, Mizuho raised their target price on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research note on Thursday, November 6th. Nine analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Cencora has a consensus rating of “Moderate Buy” and an average target price of $371.09.

Insider Activity

In related news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the sale, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is currently owned by corporate insiders.

Cencora Trading Down 0.4%

COR opened at $363.75 on Thursday. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $366.17. The firm has a market capitalization of $70.52 billion, a PE ratio of 37.42, a P/E/G ratio of 1.56 and a beta of 0.63. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The company’s 50-day moving average is $318.52 and its 200 day moving average is $301.12.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period in the prior year, the business posted $3.34 earnings per share. The company’s quarterly revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.